Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug;36(8):733-745.
doi: 10.1007/s40266-019-00680-x.

Optimizing Drug Therapies in Patients With COPD in the US Nursing Home Setting

Affiliations
Review

Optimizing Drug Therapies in Patients With COPD in the US Nursing Home Setting

Roy A Pleasants et al. Drugs Aging. .

Abstract

Chronic obstructive pulmonary disease (COPD) can be a disabling disease, and the impact on older adults is particularly evident in the nursing home setting. Chronic obstructive pulmonary disease is present in about 20% of nursing home residents, most often in women, and accounts for significant healthcare utilization including acute care visits for exacerbations and pneumonia, as well as worsening heart disease and diabetes mellitus. The emphasis on hospital readmissions is particularly important in nursing homes where institutions have quality measures that have financial implications. Optimizing drug therapies in individuals with COPD involves choosing medications that not only improve symptoms, but also decrease the risk of exacerbations. Optimizing the treatment of comorbidities such as heart disease, infections, and diabetes that may affect COPD outcomes is also an important consideration. Depending on the nursing home setting and the patient, the options for optimizing COPD drug therapies may be limited owing to patient-related factors such as cognition and physical impairment or available resources, primarily reimbursement-related issues. Choosing the best drug therapy for COPD in older adults is limited by the difficulty in assessing respiratory symptoms using standardized assessment tools and potentially decreased inspiratory ability of frail individuals. Because of cognitive and physical impediments, ensuring optimal delivery of inhaled medications into the lungs has significant challenges. Long-acting bronchodilators, inhaled corticosteroids, and roflumilast decrease the risk of exacerbations, although inhaled corticosteroids should be used judiciously in this population because of the risk of pneumonia and oropharyngeal side effects. Treatment of COPD exacerbations should occur early and consideration should be made to the benefits and risks of systemic corticosteroids and antibiotics. Clinical research in the COPD population in nursing homes is clearly lacking, and ripe for discovery of effective management strategies.

Similar articles

See all similar articles

References

    1. J Am Med Dir Assoc. 2014 Mar;15(3):151-153 - PubMed

References

    1. Eur J Heart Fail. 2007 Aug;9(8):827-33 - PubMed

References

    1. Am J Health Syst Pharm. 2011 Jul 1;68(13):1221-32 - PubMed

References

    1. Arch Intern Med. 1996 May 13;156(9):984-8 - PubMed

References

    1. Arthritis Care Res (Hoboken). 2017 Aug;69(8):1095-1110 - PubMed

References

    1. J Am Med Dir Assoc. 2012 May;13(4):390-3 - PubMed

References

    1. N C Med J. 2013 Sep-Oct;74(5):376-83 - PubMed

References

    1. J Appl Physiol (1985). 1995 May;78(5):1957-68 - PubMed

References

    1. MMWR Recomm Rep. 2018 Apr 27;67(2):1-44 - PubMed

References

    1. Lancet. 2013 Mar 2;381(9868):752-62 - PubMed

References

    1. Thorax. 2012 Nov;67(11):977-84 - PubMed

References

    1. Int J Chron Obstruct Pulmon Dis. 2019 Mar 01;14:585-595 - PubMed

References

    1. Osteoporos Int. 2014 Oct;25(10):2359-81 - PubMed

References

    1. Respir Care. 2018 Jun;63(6):708-733 - PubMed

References

    1. Scand J Respir Dis. 1976;57(4):190-6 - PubMed

References

    1. Lancet Respir Med. 2017 Sep;5(9):738-746 - PubMed

References

    1. Clin Res Cardiol. 2014 Sep;103(9):733-41 - PubMed

References

    1. J Aging Health. 2015 Apr;27(3):480-99 - PubMed

References

    1. N Engl J Med. 2018 May 03;378(18):1671-1680 - PubMed

References

    1. Respir Care. 2018 Jun;63(6):671-689 - PubMed

References

    1. J Epidemiol. 2017 Aug;27(8):347-353 - PubMed

References

    1. Am J Respir Crit Care Med. 2013 Apr 1;187(7):728-35 - PubMed

References

    1. Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S144-57 - PubMed

References

    1. J Glob Health. 2015 Dec;5(2):020415 - PubMed

References

    1. Clin Interv Aging. 2006;1(3):253-60 - PubMed

References

    1. Eur Respir Rev. 2010 Jun;19(116):113-8 - PubMed

References

    1. JAMA. 2005 Aug 10;294(6):716-24 - PubMed

References

    1. Intern Med J. 2018 Aug;48(8):931-936 - PubMed

References

    1. N Engl J Med. 1999 Jun 24;340(25):1941-7 - PubMed

References

    1. Consult Pharm. 2012 Sep;27(9):650-9 - PubMed

References

    1. Intern Med J. 2010 Mar;40(3):193-200 - PubMed

References

    1. Int J Chron Obstruct Pulmon Dis. 2013;8:305-12 - PubMed

References

    1. Ann Am Thorac Soc. 2018 May;15(5):608-614 - PubMed

References

    1. Clin Interv Aging. 2013;8:1585-90 - PubMed

References

    1. J Am Med Dir Assoc. 2011 Mar;12(3):195-203 - PubMed

References

    1. Eur J Clin Pharmacol. 2009 Jul;65(7):743-5 - PubMed

References

    1. Am Rev Respir Dis. 1993 Jul;148(1):123-6 - PubMed

References

    1. JAMA. 2013 Jun 5;309(21):2223-31 - PubMed

References

    1. Ann Phys Rehabil Med. 2010 Mar;53(2):69-76 - PubMed

References

    1. Eur J Neurol. 2015 Feb;22(2):334-40 - PubMed

References

    1. Age Ageing. 2009 Sep;38(5):537-41 - PubMed

References

    1. Age Ageing. 1988 Jul;17(4):275-8 - PubMed

References

    1. Respir Res. 2018 Oct 5;19(1):196 - PubMed

References

    1. Med Care. 2013 Aug;51(8):673-81 - PubMed

References

    1. Chest. 1989 Dec;96(6):1241-6 - PubMed

References

    1. Tuberc Respir Dis (Seoul). 2018 Jul;81(3):187-197 - PubMed

References

    1. Geriatrics. 1978 Jun;33(6):68-74 - PubMed

References

    1. Eur J Endocrinol. 2015 Jul;173(1):19-27 - PubMed

References

    1. Aging Clin Exp Res. 2018 Jun;30(6):609-616 - PubMed

References

    1. Thorax. 2016 Jan;71(1):8-14 - PubMed

References

    1. Br J Clin Pharmacol. 2015 Sep;80(3):372-80 - PubMed

References

    1. Respir Care. 2018 Oct;63(10):1302-1310 - PubMed

References

    1. Chest. 2009 Feb;135(2):368-377 - PubMed

References

    1. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56 - PubMed

References

    1. J Am Med Dir Assoc. 2014 Sep;15(9):630-4 - PubMed

References

    1. Respir Res. 2017 Jun 19;18(1):124 - PubMed

References

    1. J Am Med Dir Assoc. 2017 Nov 1;18(11):991.e5-991.e10 - PubMed

References

    1. Eur Respir J. 2017 Sep 9;50(3): - PubMed

References

    1. Am J Geriatr Pharmacother. 2009 Oct;7(5):262-70 - PubMed

References

    1. Cochrane Database Syst Rev. 2017 Jan 24;1:CD001390 - PubMed

References

    1. PLoS One. 2014 Nov 26;9(11):e113048 - PubMed

References

    1. Epidemiol Infect. 2017 Jul;145(10):2109-2121 - PubMed

References

    1. J Am Med Dir Assoc. 2019 Mar;20(3):382-383.e1 - PubMed

References

    1. J Manag Care Pharm. 2012 Oct;18(8):598-606 - PubMed

References

    1. Age Ageing. 1997 Mar;26(2):83-6 - PubMed

References

    1. Pharmacotherapy. 2005 Oct;25(10):1303-9 - PubMed

References

    1. J Gerontol A Biol Sci Med Sci. 2016 May;71(5):689-95 - PubMed

References

    1. Lancet Respir Med. 2016 Feb;4(2):149-64 - PubMed

References

    1. Vital Health Stat 3. 2016 Feb;(38):x-xii; 1-105 - PubMed

MeSH terms

LinkOut - more resources

Feedback